Bender, M. J. et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell 186, 1846–1862.e26 (2023).
Derosa, L., Routy, B., Kroemer, G. & Zitvogel, L. The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. Oncoimmunology 7, e1434468 (2018).
Derosa, L. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat. Med. 28, 315–324 (2022).
Fidelle, M. et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. Science 380, eabo2296 (2023).
Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).
Hakozaki, T. et al. The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer. Cancer Immunol. Res. 8, 1243–1250 (2020).
Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).
Messaoudene, M. et al. The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers. Nat. Commun. 15, 8083 (2024).
Park, J. S. et al. Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance. Nature 617, 377–385 (2023).
Phelps, C. M. et al. Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. Cell 188, 5680–5700.e28 (2025).
Pinato, D. J. et al. Antibiotic therapy and outcome from immune-checkpoint inhibitors. J. Immunother. Cancer 7, 287 (2019).
Routy, B. et al. The gut microbiota influences anticancer immunosurveillance and general health. Nat. Rev. Clin. Oncol. 15, 382–396 (2018).
Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
Shatila, M. et al. Gastrointestinal infection before immune checkpoint inhibition hinders treatment efficacy and increases the risk of colitis. Cancer Med. 14, e71123 (2025).
Spencer, C. N. et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374, 1632–1640 (2021).
Derosa, L. et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann. Oncol. 29, 1437–1444 (2018).
Winter, S. E. & Bäumler, A. J. Gut dysbiosis: Ecological causes and causative effects on human disease. Proc. Natl. Acad. Sci. USA 120, e2316579120 (2023).
The Human Microbiome Project Consortium Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).
The Integrative HMP (iHMP) Research Network Consortium The integrative human microbiome project. Nature 569, 641–648 (2019).
Hooks, K. B. & O’Malley, M. A. Dysbiosis and its discontents. mBio 8, e01492–17 (2017).
Olesen, S. W. & Alm, E. J. Dysbiosis is not an answer. Nat. Microbiol. 1, 16228 (2016).
Yong, E. There is no ‘healthy’ microbiome. The New York Times (2 November 2014).
Ponziani, F. R. et al. Gut dysbiosis and fecal calprotectin predict response to immune checkpoint inhibitors in patients with hepatocellular carcinoma. Hepatol. Commun. 6, 1492–1501 (2022).
Birebent, R. et al. Surrogate markers of intestinal dysfunction associated with survival in advanced cancers. Oncoimmunology 14, 2484880 (2025).
World Health Organization. Constitution of the World Health Organization 1–18 (World Health Organization, 1946).
López-Otín, C. & Kroemer, G. Hallmarks of health. Cell 184, 33–63 (2021).
Martino, C. et al. Microbiota succession throughout life from the cradle to the grave. Nat. Rev. Microbiol. 20, 707–720 (2022).
Gomez de Agüero, M. et al. The maternal microbiota drives early postnatal innate immune development. Science 351, 1296–1302 (2016).
Thorburn, A. N. et al. Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites. Nat. Commun. 6, 7320 (2015).
Rasmussen, M. A. et al. Ecological succession in the vaginal microbiota during pregnancy and birth. ISME J. 14, 2325–2335 (2020).
Ardic, C., Usta, O., Omar, E., Yıldız, C. & Memis, E. Caesarean delivery increases the risk of overweight or obesity in 2-year-old children. J. Obstet. Gynaecol. 41, 374–379 (2021).
Shao, Y. et al. Stunted microbiota and opportunistic pathogen colonization in caesarean-section birth. Nature 574, 117–121 (2019).
Stokholm, J. et al. Maturation of the gut microbiome and risk of asthma in childhood. Nat. Commun. 9, 141 (2018).
Munblit, D., Verhasselt, V. & Warner, J. O. Editorial: human milk composition and health outcomes in children. Front. Pediatr. 7, 319 (2019).
Thaiss, C. A. et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell 159, 514–529 (2014).
Thaiss, C. A. et al. Microbiota diurnal rhythmicity programs host transcriptome oscillations. Cell 167, 1495–1510.e12 (2016).
Bailey, M. T. et al. Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation. Brain Behav. Immun. 25, 397–407 (2011).
Zhao, S. et al. Adaptive evolution within gut microbiomes of healthy people. Cell Host Microbe 25, 656–667.e8 (2019).
Biagi, E. et al. Gut microbiota and extreme longevity. Curr. Biol. 26, 1480–1485 (2016).
Ghosh, T. S., Shanahan, F. & O’Toole, P. W. The gut microbiome as a modulator of healthy ageing. Nat. Rev. Gastroenterol. Hepatol. 19, 565–584 (2022).
Grajeda-Iglesias, C. et al. Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites. Aging 13, 6375–6405 (2021).
Pang, S. et al. Longevity of centenarians is reflected by the gut microbiome with youth-associated signatures. Nat. Aging 3, 436–449 (2023).
Thomas, A. M. et al. Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 583–603 (2023).
Sinha, T. et al. Analysis of 1135 gut metagenomes identifies sex-specific resistome profiles. Gut Microbes 10, 358–366 (2019).
Zhang, X. et al. Sex- and age-related trajectories of the adult human gut microbiota shared across populations of different ethnicities. Nat. Aging 1, 87–100 (2021).
Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352, 565–569 (2016).
d’Afflitto, M., Upadhyaya, A., Green, A. & Peiris, M. Association between sex hormone levels and gut microbiota composition and diversity—a systematic review. J. Clin. Gastroenterol. 56, 384–392 (2022).
Peters, B. A. et al. Menopause is associated with an altered gut microbiome and estrobolome, with implications for adverse cardiometabolic risk in the hispanic community health study/study of Latinos. mSystems 7, e0027322 (2022).
Santos-Marcos, J. A. et al. Influence of gender and menopausal status on gut microbiota. Maturitas 116, 43–53 (2018).
Zhao, H. et al. Compositional and functional features of the female premenopausal and postmenopausal gut microbiota. FEBS Lett. 593, 2655–2664 (2019).
Conforti, F. et al. Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis. J. Natl. Cancer Inst. 111, 772–781 (2019).
Conforti, F. et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 19, 737–746 (2018).
Graham, J., Abdel-Rahman, O., Choueiri, T. K. & Heng, D. Y. C. Re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer immunotherapy efficacy and patients’ sex: A systematic review and meta-analysis. Lancet Oncol 2018; 19:737–46: Outcomes of metastatic renal cell carcinoma by gender: Contrasting results from the International mRCC Database Consortium. Eur. Urol. 74, e139–e140 (2018).
Conforti, F. et al. Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y. C. Heng’s Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol 2018;19:737–746: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium. Eur. Urol. 75, e34–e35 (2019).
Haupt, S., Caramia, F., Klein, S. L., Rubin, J. B. & Haupt, Y. Sex disparities matter in cancer development and therapy. Nat. Rev. Cancer 21, 393–407 (2021).
Ye, Y. et al. Sex-associated molecular differences for cancer immunotherapy. Nat. Commun. 11, 1779 (2020).
Wallis, C. J. D. et al. Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers. JAMA Oncol. 5, 529–536 (2019).
Gacesa, R. et al. Environmental factors shaping the gut microbiome in a Dutch population. Nature 604, 732–739 (2022).
Rothschild, D. et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 555, 210–215 (2018).
Turpin, W. et al. Association of host genome with intestinal microbial composition in a large healthy cohort. Nat. Genet. 48, 1413–1417 (2016).
Lopera-Maya, E. A. et al. Effect of host genetics on the gut microbiome in 7,738 participants of the Dutch Microbiome Project. Nat. Genet. 54, 143–151 (2022).
Qin, Y. et al. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. Nat. Genet. 54, 134–142 (2022).
Kurilshikov, A. et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat. Genet. 53, 156–165 (2021).
Zhernakova, D. V. et al. Host genetic regulation of human gut microbial structural variation. Nature 625, 813–821 (2024).
Goodrich, J. K. et al. Human genetics shape the gut microbiome. Cell 159, 789–799 (2014).
Goodrich, J. K. et al. Genetic determinants of the gut microbiome in UK twins. Cell Host Microbe 19, 731–743 (2016).
De Filippo, C. et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. USA 107, 14691–14696 (2010).
Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature 486, 222–227 (2012).
Deschasaux, M. et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. Nat. Med. 24, 1526–1531 (2018).
Falony, G. et al. Population-level analysis of gut microbiome variation. Science 352, 560–564 (2016).
He, Y. et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat. Med. 24, 1532–1535 (2018).
Mueller, S. et al. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl. Environ. Microbiol. 72, 1027–1033 (2006).
Monda, V. et al. Exercise modifies the gut microbiota with positive health effects. Oxid. Med. Cell. Longev. 2017, 3831972 (2017).
Sohail, M. U., Yassine, H. M., Sohail, A. & Thani, A. A. A. Impact of physical exercise on gut microbiome, inflammation, and the pathobiology of metabolic disorders. Rev. Diabet. Stud. 15, 35–48 (2019).
Varghese, S., Rao, S., Khattak, A., Zamir, F. & Chaari, A. Physical exercise and the gut microbiome: A bidirectional relationship influencing health and performance. Nutrients 16, 3663 (2024).
GBD 2017 Diet Collaborators Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 393, 1958–1972 (2019).
David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014).
Do, M. H., Lee, E., Oh, M. J., Kim, Y. & Park, H. Y. High-glucose or -fructose diet cause changes of the gut microbiota and metabolic disorders in mice without body weight change. Nutrients 10, 761 (2018).
Fackelmann, G. et al. Gut microbiome signatures of vegan, vegetarian and omnivore diets and associated health outcomes across 21,561 individuals. Nat. Microbiol. 10, 41–52 (2025).
Fajstova, A. et al. Diet rich in simple sugars promotes pro-inflammatory response via gut microbiota alteration and TLR4 signaling. Cells 9, 2701 (2020).
de Vos, W. M., Tilg, H., Van Hul, M. & Cani, P. D. Gut microbiome and health: mechanistic insights. Gut 71, 1020–1032 (2022).
Oliver, A. et al. High-fiber, whole-food dietary intervention alters the human gut microbiome but not fecal short-chain fatty acids. mSystems 6, e00115–e00121 (2021).
Siddiqui, M. T. & Cresci, G. A. M. The immunomodulatory functions of butyrate. J. Inflamm. Res. 14, 6025–6041 (2021).
Ferrere, G. et al. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight 6, e145207 (2021).
Sofi, F., Cesari, F., Abbate, R., Gensini, G. F. & Casini, A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 337, a1344 (2008).
Wang, D. D. et al. The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk. Nat. Med. 27, 333–343 (2021).
Alves Costa Silva, C., Fidelle, M., Almonte, A. A., Derosa, L. & Zitvogel, L. Gut microbiota-related biomarkers in immuno-oncology. Annu. Rev. Pharm. Toxicol. 65, 333–354 (2025).
Almonte, A. A., Thomas, S. & Zitvogel, L. Microbiota-centered interventions to boost immune checkpoint blockade therapies. J. Exp. Med. 222, e20250378 (2025).
Rousseau, A. et al. Concomitant comedications and survival with first-line pembrolizumab in advanced non-small-cell lung cancer. JAMA Netw. Open 8, e2529225 (2025).
Montégut, L. et al. Benzodiazepines interfere with the efficacy of pembrolizumab-based cancer immunotherapy. Results of a nationwide cohort study including over 50,000 participants with advanced lung cancer. Oncoimmunology 14, 2528955 (2025).
Vich Vila, A. et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat. Commun. 11, 362 (2020).
Bavishi, C. & Dupont, H. L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment. Pharm. Ther. 34, 1269–1281 (2011).
Clooney, A. G. et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment. Pharm. Ther. 43, 974–984 (2016).
Jackson, M. A. et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65, 749–756 (2016).
Lin, Y. T. et al. Anti-acid drug treatment induces changes in the gut microbiome composition of hemodialysis patients. Microorganisms 9, 286 (2021).
Seto, C. T., Jeraldo, P., Orenstein, R., Chia, N. & DiBaise, J. K. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome 2, 42 (2014).
Singh, G. et al. The effect of gastric acid suppression on probiotic colonization in a double blinded randomized clinical trial. Clin. Nutr. ESPEN 47, 70–77 (2022).
Palleja, A. et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat. Microbiol. 3, 1255–1265 (2018).
Aasmets, O. et al. A hidden confounder for microbiome studies: medications used years before sample collection. mSystems 10, e00541–25 (2025).
Ricaurte, D. et al. High-throughput transcriptomics of 409 bacteria-drug pairs reveals drivers of gut microbiota perturbation. Nat. Microbiol. 9, 561–575 (2024).
Algavi, Y. M. & Borenstein, E. A data-driven approach for predicting the impact of drugs on the human microbiome. Nat. Commun. 14, 3614 (2023).
Nagata, N. et al. Population-level metagenomics uncovers distinct effects of multiple medications on the human gut microbiome. Gastroenterology 163, 1038–1052 (2022).
Ticinesi, A. et al. Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci. Rep. 7, 11102 (2017).
Elkrief, A. et al. Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. NPJ Precis. Oncol. 8, 143 (2024).
Lopes, S. et al. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis. Front. Immunol. 14, 1070076 (2023).
Montégut, L. et al. Benzodiazepines compromise the outcome of cancer immunotherapy. Oncoimmunology 13, 2413719 (2024).
Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023 (2006).
Hsu, C. L. & Schnabl, B. The gut-liver axis and gut microbiota in health and liver disease. Nat. Rev. Microbiol. 21, 719–733 (2023).
Crudele, L., Gadaleta, R. M., Cariello, M. & Moschetta, A. Gut microbiota in the pathogenesis and therapeutic approaches of diabetes. EBioMedicine 97, 104821 (2023).
Iliev, I. D., Ananthakrishnan, A. N. & Guo, C. J. Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities. Nat. Rev. Microbiol. 23, 509–524 (2025).
Masenga, S. K. et al. Recent advances in modulation of cardiovascular diseases by the gut microbiota. J. Hum. Hypertens. 36, 952–959 (2022).
Bindels, L. B. et al. Increased gut permeability in cancer cachexia: mechanisms and clinical relevance. Oncotarget 9, 18224–18238 (2018).
Pötgens, S. A. et al. Klebsiella oxytoca expands in cancer cachexia and acts as a gut pathobiont contributing to intestinal dysfunction. Sci. Rep. 8, 12321 (2018).
Yonekura, S. et al. Cancer induces a stress ileopathy depending on β-adrenergic receptors and promoting dysbiosis that contributes to carcinogenesis. Cancer Discov. 12, 1128–1151 (2022).
Kim, H. C. et al. Gut microbiota dysbiosis induced by brain tumors modulates the efficacy of immunotherapy. Cell Rep. 44, 115825 (2025).
Valles-Colomer, M. et al. Neuroblastoma is associated with alterations in gut microbiome composition subsequent to maternal microbial seeding. EBioMedicine 99, 104917 (2024).
Kokolus, K. M. et al. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. Oncoimmunology 7, e1405205 (2018).
Wangel, A. G. & Deller, D. J. Malabsorption syndrome associated with carcinoma of the bronchus. Gut 6, 73–76 (1965).
Jukic, A., Bakiri, L., Wagner, E. F., Tilg, H. & Adolph, T. E. Calprotectin: from biomarker to biological function. Gut 70, 1978–1988 (2021).
Lanas, Á et al. Fecal occult blood and calprotectin testing to prioritize primary care patients for colonoscopy referral: the advantage study. United Eur. Gastroenterol. J. 11, 692–699 (2023).
Bromke, M. A., Neubauer, K., Kempiński, R. & Krzystek-Korpacka, M. Faecal calprotectin in assessment of mucosal healing in adults with inflammatory bowel disease: a meta-analysis. J. Clin. Med. 10, 2203 (2021).
Heinzel, S. et al. Elevated fecal calprotectin is associated with gut microbial dysbiosis, altered serum markers and clinical outcomes in older individuals. Sci. Rep. 14, 13513 (2024).
Rocha, I. M. G. D. et al. Pro-inflammatory diet is correlated with high Veillonella rogosae, gut inflammation and clinical relapse of inflammatory bowel disease. Nutrients 15, 4148 (2023).
Lu, F., Inoue, K., Kato, J., Minamishima, S. & Morisaki, H. Functions and regulation of lipocalin-2 in gut-origin sepsis: a narrative review. Crit. Care 23, 269 (2019).
Sugi, K., Saitoh, O., Hirata, I. & Katsu, K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am. J. Gastroenterol. 91, 927–934 (1996).
Bachem, A. et al. Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8+ T cells. Immunity 51, 285–297.e5 (2019).
Zhu, X. et al. Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell. Gut Microbes 15, 2249143 (2023).
Alvandi, E., Wong, W. K. M., Joglekar, M. V., Spring, K. J. & Hardikar, A. A. Short-chain fatty acid concentrations in the incidence and risk-stratification of colorectal cancer: a systematic review and meta-analysis. BMC Med. 20, 323 (2022).
Parada Venegas, D. et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front. Immunol. 10, 277 (2019).
Lee, M. H. et al. How bile acids and the microbiota interact to shape host immunity. Nat. Rev. Immunol. 24, 798–809 (2024).
Casado-Bedmar, M. & Viennois, E. MicroRNA and gut microbiota: Tiny but mighty—novel insights into their cross-talk in inflammatory bowel disease pathogenesis and therapeutics. J. Crohns Colitis 16, 992–1005 (2021).
McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545–556 (2022).
Marino, M. et al. Serum zonulin and colorectal cancer risk. Sci. Rep. 14, 28171 (2024).
Fux, A. C. et al. Heterogeneity of lipopolysaccharide as source of variability in bioassays and LPS-binding proteins as remedy. Int. J. Mol. Sci. 24, 8395 (2023).
Sardar, P. et al. Gut microbiota-derived hexa-acylated lipopolysaccharides enhance cancer immunotherapy responses. Nat. Microbiol. 10, 795–807 (2025).
Sun, L. et al. Akkermansia muciniphila-derived hypoacylated rough-type lipopolysaccharides alleviate diet-induced obesity via activation of TLR4-IL-23-IL-22 immune axis. Imeta 4, e70066 (2025).
Garcia-Vello, P. et al. The lipooligosaccharide of the gut symbiont Akkermansia muciniphila exhibits a remarkable structure and TLR signaling capacity. Nat. Commun. 15, 8411 (2024).
Duerr, C. U. et al. O-antigen delays lipopolysaccharide recognition and impairs antibacterial host defense in murine intestinal epithelial cells. PLoS Pathog. 5, e1000567 (2009).
Koutsounas, I., Kaltsa, G., Siakavellas, S. I. & Bamias, G. Markers of bacterial translocation in end-stage liver disease. World J. Hepatol. 7, 2264–2273 (2015).
Tabung, F. K. et al. Influence of dietary patterns on plasma soluble CD14, a surrogate marker of gut barrier dysfunction. Curr. Dev. Nutr. 1, e001396 (2017).
Moreno-Navarrete, J. M. et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int. J. Obes. 36, 1442–1449 (2012).
Liang, H., Hussey, S. E., Sanchez-Avila, A., Tantiwong, P. & Musi, N. Effect of lipopolysaccharide on inflammation and insulin action in human muscle. PLoS One 8, e63983 (2013).
Fedirko, V. et al. Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: a nested case-control study. BMC Med. 15, 72 (2017).
Zhao, S. et al. Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice. J. Mol. Endocrinol. 58, 1–14 (2017).
Marcos-Kovandzic, L. et al. Gut microbiota modulation through Akkermansia spp. supplementation increases CAR T-cell potency. Cancer Discov. 15, 1905–1926 (2025).
Wu, G. et al. A core microbiome signature as an indicator of health. Cell 187, 6550–6565.e11 (2024).
Gamrath, L. et al. Role of the microbiome and diet for response to cancer checkpoint immunotherapy: a narrative review of clinical trials. Curr. Oncol. Rep. 27, 45–58 (2025).
Yang, Y. et al. Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC. NPJ Biofilms Microbiomes 11, 146 (2025).
Murayama, M. et al. Isobutyric acid enhances the anti-tumor effect of anti-PD-1 antibody. Sci. Rep. 14, 11325 (2024).
Kang, X. et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+ T cells. Gut 72, 2112–2122 (2023).
Coutzac, C. et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat. Commun. 11, 2168 (2020).
Zhu, R., Gu, S., Tao, Y. & Zhang, Y. Butyrate confers colorectal cancer cell resistance to anti-PD-1 therapy by promoting CPT1A-mediated fatty acid oxidation. Discov. Oncol. 16, 935 (2025).
Chelvanambi, M. & Wargo, J. A. MAdCAM-1: a newly identified microbial “gut check” for T cells. Trends Immunol. 44, 568–570 (2023).
Saliby, R. M. et al. Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): results from a randomized first-line clinical trial. J. Clin. Oncol. 43, 4512 (2025).
Agus, A., Planchais, J. & Sokol, H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 23, 716–724 (2018).
Janeiro, M. H., Ramírez, M. J., Milagro, F. I., Martínez, J. A. & Solas, M. Implication of trimethylamine N-oxide (TMAO) in disease: Potential biomarker or new therapeutic target. Nutrients 10, 1398 (2018).
Tang, W. H. W. & Hazen, S. L. Microbiome, trimethylamine N-oxide, and cardiometabolic disease. Transl. Res. 179, 108–115 (2017).
Lee, J. et al. Antibiotic-induced intestinal microbiota depletion can attenuate the acute kidney injury to chronic kidney disease transition via NADPH oxidase 2 and trimethylamine-N-oxide inhibition. Kidney Int. 105, 1239–1253 (2024).
Wang, H. et al. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. Cell Metab. 34, 581–594.e8 (2022).
Mirji, G. et al. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Sci. Immunol. 7, eabn0704 (2022).
Gupta, V. K. et al. A predictive index for health status using species-level gut microbiome profiling. Nat. Commun. 11, 4635 (2020).
Zitvogel, L. & Kroemer, G. Cancer and the metaorganism. Cancer Discov. 14, 658–662 (2024).
Manor, O. et al. Health and disease markers correlate with gut microbiome composition across thousands of people. Nat. Commun. 11, 5206 (2020).
Duvallet, C., Gibbons, S. M., Gurry, T., Irizarry, R. A. & Alm, E. J. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. Nat. Commun. 8, 1784 (2017).
Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480–484 (2009).
Matsuoka, K. & Kanai, T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 37, 47–55 (2015).
Walters, W. A., Xu, Z. & Knight, R. Meta-analyses of human gut microbes associated with obesity and IBD. FEBS Lett. 588, 4223–4233 (2014).
Arumugam, M. et al. Enterotypes of the human gut microbiome. Nature 473, 174–180 (2011).
Cai, J. A. et al. Gut microbiota enterotypes mediate the effects of dietary patterns on colorectal neoplasm risk in a chinese population. Nutrients 15, 2940 (2023).
Kovatcheva-Datchary, P. et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of Prevotella. Cell Metab. 22, 971–982 (2015).
Thomas, A. M. et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat. Med. 25, 667–678 (2019).
Park, S., Zhang, T. & Kang, S. Fecal microbiota composition, their interactions, and metagenome function in US adults with type 2 diabetes according to enterotypes. Int. J. Mol. Sci. 24, 9533 (2023).
Wang, J. et al. Enterotype bacteroides is associated with a high risk in patients with diabetes: a pilot study. J. Diabetes Res. 2020, 6047145 (2020).
Lee, S. et al. Different reactions in each enterotype depending on the intake of probiotic yogurt powder. Microorganisms 9, 1277 (2021).
Heintz-Buschart, A. et al. Integrated multi-omics of the human gut microbiome in a case study of familial type 1 diabetes. Nat. Microbiol. 2, 16180 (2016).
Xiao, L., Wang, J., Zheng, J., Li, X. & Zhao, F. Deterministic transition of enterotypes shapes the infant gut microbiome at an early age. Genome Biol. 22, 243 (2021).
Costea, P. I. et al. Enterotypes in the landscape of gut microbial community composition. Nat. Microbiol. 3, 8–16 (2018).
Koren, O. et al. A guide to enterotypes across the human body: meta-analysis of microbial community structures in human microbiome datasets. PLoS Comput. Biol. 9, e1002863 (2013).
Rivas-Santisteban, J. et al. Quantifying microbial guilds. ISME Commun. 4, ycae042 (2024).
Wu, G., Zhao, N., Zhang, C., Lam, Y. Y. & Zhao, L. Guild-based analysis for understanding gut microbiome in human health and diseases. Genome Med. 13, 22 (2021).
Zhao, L., Wu, G. & Zhao, N. Guild-based approach for mitigating information loss and distortion issues in microbiome analysis. J. Clin. Invest. 134, e185395 (2024).
Guo, M. et al. Guild-level microbiome signature associated with COVID-19 severity and prognosis. mBio 14, e0351922 (2023).
Zhao, L. et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science 359, 1151–1156 (2018).
Clavijo-Salomon, M. A. & Trinchieri, G. Unlocking the power of the microbiome for successful cancer immunotherapy. J. Immunother. Cancer 13, e011281 (2025).
Tang, S. et al. Guild-level signature of gut microbiome for diabetic kidney disease. mBio 15, e0073524 (2024).
Jia, L. et al. A transmissible γδ intraepithelial lymphocyte hyperproliferative phenotype is associated with the intestinal microbiota and confers protection against acute infection. Muc. Immunol. 15, 772–782 (2022).
Derosa, L. et al. Microbiota-centered interventions: the next breakthrough in immuno-oncology? Cancer Discov. 11, 2396–2412 (2021).
Goel, A. et al. Toward a health-associated core keystone index for the human gut microbiome. Cell Rep. 44, 115378 (2025).
Macandog, A. D. G. et al. Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients. Cell Host Microbe 32, 2004–2018.e9 (2024).
Björk, J. R. et al. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. Nat. Med. 30, 785–796 (2024).
Ferrari, V. et al. Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I. Cancer Cell 41, 1717–1730.e4 (2023).
Rice, T. A. et al. Interspecies commensal interactions have nonlinear impacts on host immunity. Cell Host Microbe 30, 988–1002.e6 (2022).
Bajaj, J. S. et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J. Hepatol. 60, 940–947 (2014).
Casén, C. et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharm. Ther. 42, 71–83 (2015).
Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569, 655–662 (2019).
Saffouri, G. B. et al. Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat. Commun. 10, 2012 (2019).
Guo, Z. et al. Intestinal microbiota distinguish gout patients from healthy humans. Sci. Rep. 6, 20602 (2016).
Mayerhofer, C. C. K. et al. Low fibre intake is associated with gut microbiota alterations in chronic heart failure. ESC Heart Fail. 7, 456–466 (2020).
Xia, G. H. et al. Stroke Dysbiosis Index (SDI) in gut microbiome are associated with brain injury and prognosis of stroke. Front. Neurol. 10, 397 (2019).
Derosa, L. et al. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome. Cell 187, 3373–3389.e16 (2024).
Nakatsu, G. et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat. Commun. 6, 8727 (2015).
Chang, D. et al. Gut Microbiome Wellness Index 2 enhances health status prediction from gut microbiome taxonomic profiles. Nat. Commun. 15, 7447 (2024).
Valdés-Mas, R. et al. Metagenome-informed metaproteomics of the human gut microbiome, host, and dietary exposome uncovers signatures of health and inflammatory bowel disease. Cell 188, 1062–1083.e36 (2025).
Wei, S., Bahl, M. I., Baunwall, S. M. D., Hvas, C. L. & Licht, T. R. Determining gut microbial dysbiosis: a review of applied indexes for assessment of intestinal microbiota imbalances. Appl. Environ. Microbiol. 87, e00395–21 (2021).
Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 15, 382–392 (2014).
Duncan, S. H., Barcenilla, A., Stewart, C. S., Pryde, S. E. & Flint, H. J. Acetate utilization and butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the human large intestine. Appl. Environ. Microbiol. 68, 5186–5190 (2002).
Zitvogel, L. et al. Impact of the ONCOBIOME network in cancer microbiome research. Nat. Med. 31, 1085–1098 (2025).
Elkrief, A. et al. The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development. Nat. Rev. Drug Discov. 24, 685–704 (2025).
Vandeputte, D. et al. Quantitative microbiome profiling links gut community variation to microbial load. Nature 551, 507–511 (2017).
Tito, R. Y. et al. Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development. Nat. Med. 30, 1339–1348 (2024).
Vieira-Silva, S. et al. Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses. Nat. Microbiol. 4, 1826–1831 (2019).
Wagner, S. et al. Absolute abundance calculation enhances the significance of microbiome data in antibiotic treatment studies. Front. Microbiol. 16, 1481197 (2025).
Nishijima, S. et al. Fecal microbial load is a major determinant of gut microbiome variation and a confounder for disease associations. Cell 188, 222–236.e15 (2025).
Blanco-Míguez, A. et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat. Biotechnol. 41, 1633–1644 (2023).
Martín, R. et al. Faecalibacterium: a bacterial genus with promising human health applications. FEMS Microbiol. Rev. 47, fuad039 (2023).
Lu, H. et al. Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-κB axis. Cell Host Microbe 30, 1139–1150.e7 (2022).
Notting, F., Pirovano, W., Sybesma, W. & Kort, R. The butyrate-producing and spore-forming bacterial genus Coprococcus as a potential biomarker for neurological disorders. Gut Microbiome 4, e16 (2023).
Scott, K. P. et al. Substrate-driven gene expression in Roseburia inulinivorans: Importance of inducible enzymes in the utilization of inulin and starch. Proc. Natl. Acad. Sci. USA 108, 4672–4679 (2011).
Vital, M., Karch, A. & Pieper, D. H. Colonic butyrate-producing communities in humans: an overview using omics data. mSystems 2, e00130–17 (2017).
Kim, C. H. Complex regulatory effects of gut microbial short-chain fatty acids on immune tolerance and autoimmunity. Cell Mol. Immunol. 20, 341–350 (2023).
Litvak, Y., Byndloss, M. X. & Bäumler, A. J. Colonocyte metabolism shapes the gut microbiota. Science 362, eaat9076 (2018).
Zhu, Z. et al. Microbiome and spatially resolved metabolomics analysis reveal the anticancer role of gut Akkermansia muciniphila by crosstalk with intratumoral microbiota and reprogramming tumoral metabolism in mice. Gut Microbes 15, 2166700 (2023).
Zhu, Z. et al. Landscape of tumoral ecosystem for enhanced anti-PD-1 immunotherapy by gut Akkermansia muciniphila. Cell Rep. 43, 114306 (2024).
Pasolli, E. et al. Accessible, curated metagenomic data through ExperimentHub. Nat. Methods 14, 1023–1024 (2017).
Antoniotti, C. et al. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. BMC Cancer 20, 683 (2020).
Antoniotti, C. et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 23, 876–887 (2022).
Antoniotti, C. et al. Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: Updated and overall survival results of the ATEZOTRIBE study. J. Clin. Oncol. 42, 2637–2644 (2024).
Watson, A. R. et al. Metabolic independence drives gut microbial colonization and resilience in health and disease. Genome Biol. 24, 78 (2023).
Routy, B. et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat. Med. 29, 2121–2132 (2023).
Schmidt, T. S. B. et al. Drivers and determinants of strain dynamics following fecal microbiota transplantation. Nat. Med. 28, 1902–1912 (2022).
Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021).
Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients. Science 371, 595–602 (2021).
Elkrief, A. et al. Immune-related colitis is associated with fecal microbial dysbiosis and can be mitigated by fecal microbiota transplantation. Cancer Immunol. Res. 12, 308–321 (2024).
Ianiro, G. et al. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. Nat. Med. 28, 1913–1923 (2022).
Elkrief, A. & Routy, B. First clinical proof-of-concept that FMT can overcome resistance to ICIs. Nat. Rev. Clin. Oncol. 18, 325–326 (2021).
Elkrief, A. et al. Gut microbiota in immuno-oncology: a practical guide for medical oncologists with a focus on antibiotics stewardship. Am. Soc. Clin. Oncol. Educ. Book 45, e472902 (2025).
Stein-Thoeringer, C. K. et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat. Med. 29, 906–916 (2023).
Smith, M. et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat. Med. 28, 713–723 (2022).
Chang, C.-C., Hayase, E. & Jenq, R. R. The role of microbiota in allogeneic hematopoietic stem cell transplantation. Expert Opin. Biol. Ther. 21, 1121–1131 (2021).
Varanasi, S. K. et al. Bile acid synthesis impedes tumor-specific T cell responses during liver cancer. Science 387, 192–201 (2025).
Bertocchi, A. et al. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell 39, 708–724.e11 (2021).
Galván-Peña, S., Zhu, Y., Hanna, B. S., Mathis, D. & Benoist, C. A dynamic atlas of immunocyte migration from the gut. Sci. Immunol. 9, eadi0672 (2024).
Di Luccia, B. et al. TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti-PD-1 tumor immunotherapy. Sci. Immunol. 9, eadi5374 (2024).
Carrier, A. et al. Gut microbiota: a new factor modulating the immunizing potential of viral and cancer vaccines. Res. Sq. https://doi.org/10.21203/rs.3.rs-4294379/v1 (2025).